W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

According to a second object of the invention, there is provided a process for
the preparation of the compounds of the invention.
In particular, said method includes the step of providing an appropriate alcohol
M (suitably protected, if required) and a suitable precursor of the D moiety,
such as, for instance, an epoxide, which can be reacted with M to give the M-D
element. This in turn is further coupled to a suitably protected M' moiety, using,
for instance, a glycosylation reaction, thus yielding a new entity, which is then
treated to remove the protecting groups of both the M and M' moieties and
optionally reduced to provide the final M'-D-M entity. This is then added to a
solution of the scaffold, which already bears the linker Y moiety, in order to
obtain a compound of the invention.
In the above mentioned cases, wherein in the compound of formula (I) the Z
scaffold is represented by pentaerythhtol or bispentaerythritol dendrimers and
Q is a 1, 2 , 3-triazole, the preparation process include the step wherein a
starting pseudo-saccharidic moiety corresponding to the X moiety but bearing
an azide (-N 3 ) terminal residue is coupled via a 1,3-dipolar cycloaddition with
the dendrimer moiety.
In a third object of the invention, there are disclosed the compounds of formula
(I) as antiinfective and anti-viral medicaments against HIV virus (Human
Immunodeficiency Virus), Dengue virus, Ebola virus, Hepatitis C virus, SARS
and Mycobacterium tuberculosis.
In another aspect of said third object, there are provided the compounds of
formula (Ia) as antiinfective and anti-viral medicaments against HIV virus
(Human Immunodeficiency Virus), Dengue virus, Ebola virus, Hepatitis C virus,
SARS and Mycobacterium tuberculosis infections.
In a further aspect of the present invention, there are the compounds of
formula (Ib) as antiinfective and anti-viral medicaments against HIV virus